ea0026p216 | Pituitary | ECE2011
van der Lely A J
, Lundgren F
, Biller B M K
, Brue T
, Cara J
, Ghigo E
, Hadavi J Hey
, Rajicic N
, Saller Bernhard
, Sanocki John
, Strasburger Christian
, Webb Susan
, Haggstrom Maria Koltowska
Introduction: Somavert is a GH receptor blocker, which inhibits hepatic production of IGF1. While it has been approved for the treatment of acromegaly since 2003 there are few data regarding its effects in everyday clinical practice.Methods/design: ACROSTUDY is an open-label, international, prospective, non-interventional, post-marketing surveillance study monitoring the long-term safety and efficacy of Somavert.Results: As of Dece...